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An atlas of microRNA expression patterns and regulators is produced by deep 2 
sequencing of short RNAs in human and mouse cells. 3 
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  112 
MicroRNAs (miRNAs) are short non-coding RNAs with key roles in cellular 113 
regulation. As part of the fifth edition of the Functional Annotation of 114 
Mammalian Genome (FANTOM5) project, we created an integrated expression 115 
atlas of miRNAs and their promoters by deep sequencing 492 short RNA (sRNA) 116 
libraries, with matching Cap Analysis Gene Expression (CAGE) data, from 396 117 
human and 47 mouse RNA samples. Promoters were identified for 1,357 human 118 
and 804 mouse miRNAs and showed strong sequence conservation between 119 
species. We also found that primary and mature miRNA expression levels were 120 
correlated, allowing us to use the primary miRNA measurements as a proxy for 121 
mature miRNA levels in a total of 1,829 human and 1,029 mouse CAGE 122 
libraries. We thus provide a broad atlas of miRNA expression and promoters in 123 
primary mammalian cells, establishing a foundation for detailed analysis of 124 
miRNA expression patterns and transcriptional control regions.   125 
MicroRNAs1 (miRNAs) are a class of short (21-23 nt) non-coding RNAs with key 126 
roles in a wide range of biological processes including development and 127 
differentiation2,3, immunity4, reproduction5, and longevity6. Dysregulation of miRNA 128 
expression has been implicated in numerous diseases7, including cancer8,9. A detailed 129 
characterization of the expression profile of miRNAs across cell types and tissues is a 130 
fundamental requirement for understanding the function of miRNAs and their 131 
potential role in health and disease. 132 
 133 
MicroRNAs inhibit specific mRNAs by binding to complementary sequences, usually 134 
located in the 3’ UTR, leading to mRNA destabilization and a reduction in their 135 
translation output10. In the canonical miRNA biogenesis pathway1,11, a primary 136 
miRNA transcript (pri-miRNA) is cleaved by the endoribonuclease Drosha in the 137 
nucleus to excise the precursor miRNA (pre-miRNA), which is exported to the 138 
cytoplasm. The pre-miRNA has a characteristic hairpin secondary structure that is 139 
recognized and cleaved in the cytoplasm by the endoribonuclease Dicer, releasing the 140 
mature miRNA. 141 
 142 
Currently, the miRBase reference database of miRNAs12 lists 1,881 pre-miRNAs in 143 
human; around half (54%) are produced from intergenic non-coding pri-miRNA 144 
transcripts, while the remaining 46% are excised from the introns of protein-coding 145 
transcripts. A small proportion (6%) of human mature miRNAs annotated in miRBase 146 
are located in multiple pre-miRNAs encoded in different genomic loci. 147 
 148 
Several high-throughput approaches are available to measure the expression levels of 149 
mature miRNAs, including high-throughput qPCR, microarray, and next-generation 150 
sequencing methods13. Profiling pri-miRNAs, which is more challenging due to their 151 
transient character, has been accomplished by RNAseq in cells expressing dominant-152 
negative Drosha14. Additionally, since most pri-miRNAs are produced by RNA 153 
polymerase II and therefore have a 5’ cap11, they are amenable to Cap Analysis Gene 154 
Expression (CAGE) profiling15,16, which identifies the pri-miRNA transcription start 155 
site and therefore the promoter region, while directly quantitating the pri-miRNA 156 
expression level. 157 
 158 
Here, we analyze 492 sRNA sequencing libraries to evaluate the expression patterns 159 
of miRNAs in mammalian cells, with a particular emphasis on human primary cells. 160 
Each sRNA library was matched to a CAGE library produced from the same RNA 161 
sample, allowing us to create an integrated expression atlas of miRNAs and their 162 
promoters. The expression atlas can be accessed through a web interface at 163 
http://fantom.gsc.riken.jp/5/suppl/De_Rie_et_al_2017/). This work is part of the fifth 164 
edition of the Functional Annotation of Mammalian Genome project 165 
(FANTOM5)17,18.  166 
Results 167 
Matched miRNA and CAGE expression profiles 168 
In FANTOM5, a large collection of human and mouse primary cell types, cell lines, 169 
and tissues was profiled by CAGE to identify mRNA and long non-coding RNA 170 
transcription start sites and expression levels across a wide variety of biological 171 
states17. Here, as a complementary data set, we produced 293 sRNA sequencing 172 
libraries using FANTOM5 RNA samples from human primary cells, as well as 87 173 
sRNA libraries from RNA samples of six time courses of stimulated human cells18 174 
(Table 1, S1 & S2). We also incorporated previously produced CAGE and sRNA 175 
sequencing libraries generated from human embryonic and induced pluripotent stem 176 
cells19 (Table 1 & S1) in our analysis. In total, our sRNA sequencing data set 177 
encompassed 121 distinct human cell types. In addition, we produced 6 sRNA 178 
sequencing libraries from human tissues, and 42 sRNA libraries from mouse samples 179 
(Table 1, S1 & S2). Most sRNA libraries were produced in biological triplicate. A 180 
matching CAGE library17-19 generated from the same RNA sample was available for 181 
492 of the 500 sRNA libraries analyzed here (Table S3). 182 
  183 
Establishing a robust set of miRNAs 184 
Across the sRNA libraries, expression was confirmed for 98% (1842/1877) of human 185 
and 95% (1124/1186) of mouse pre-miRNAs annotated in release 21 of the miRBase 186 
database12. To assess the confidence level of annotated miRNAs, the miRBase 187 
curators defined a set of five rules evaluating their secondary structure and expression 188 
properties (Table 2), and used these rules to mark 295 human pre-miRNAs as high-189 
confidence annotations12. Applying these rules to the FANTOM5 sRNA data, we 190 
found that 571 human pre-miRNAs satisfied all five high-confidence rules, 224 met 191 
four of them, and 1076 violated two or more rules (Figure 1a). The 795 human and 192 
502 mouse (Figure S1) pre-miRNAs satisfying at least 4 out of the 5 high-confidence 193 
rules were defined as the FANTOM5 robust set, and the remaining 1076 human and 194 
684 mouse pre-miRNAs as the permissive set (Table S4 and Table S5). The robust set 195 
encompasses 735 human and 438 mouse mature miRNAs, and covers more than 90% 196 
of the high-confidence pre-miRNAs in miRBase (Figures S2 and S3), 90% of 197 
miRNAs well characterized in the scientific literature (Figure S4), as well as 91% 198 
(human) and 88% (mouse) of pre-miRNAs included in the manually curated 199 
MirGeneDB database20 (Figure S5).  200 
 201 
CAGE detects 3’ cleavage products of Drosha  202 
In zebrafish, the Drosha cleavage site at the 3’ end of pre-miRNAs was recently found 203 
to be characterized by a distinctive CAGE peak21. We similarly observed a CAGE 204 
peak immediately downstream of the 3’ end of human pre-miRNA loci in the 205 
ENCODE CAGE data22, and a slightly wider CAGE peak starting 1 nucleotide 206 
downstream in the FANTOM5 CAGE data17,18 (Figure 1b, c, human; Figure S6, 207 
mouse); the discrepancy between the ENCODE and FANTOM5 CAGE data is 208 
expected because of differences in the sequencer technologies employed (Figure S7). 209 
The ENCODE CAGE peak was found immediately downstream of the 3’ end of the 210 
pre-miRNA locus (Figure S8) for 19 out of 25 pre-miRNAs with a full-length 211 
sequence in the FANTOM4 sRNA sequencing libraries23, confirming that the CAGE 212 
peak marks the Drosha cleavage site. FANTOM5 and ENCODE CAGE tags at the 213 
peak were enriched in the nucleus (Figure S9), consistent with processing by Drosha. 214 
CAGE peaks were absent at the 3’ end of pre-miRNA loci encoding mirtrons (Figure 215 
S10, human; Figure S11, mouse), which are excised by the spliceosomal machinery 216 
instead of by Drosha24. 217 
 218 
To rule out the possibility that these CAGE tags originated from an independent 219 
transcript, we analyzed the first nucleotide of the CAGE tags at the Drosha cleavage 220 
site. Most CAGE tags originating from a transcription start site have an additional 221 
guanine as their first nucleotide, as the 7-methylguanosine cap at the 5’ end of 222 
transcripts produced by RNA polymerase II can be recognized as a guanine nucleotide 223 
during reverse transcription (Figure S7). No such additional guanine nucleotides were 224 
found at the Drosha CAGE peak (Figure S12), confirming that the detected RNAs 225 
were not due to an independent transcription initiation event. The lack of guanine 226 
nucleotide enrichment also suggested that the 3’ Drosha cleavage products were 227 
uncapped RNAs that were nonetheless observed to some extent in the CAGE library 228 
due to their cellular abundance. Alternatively, these RNAs may have a 229 
hypermethylated cap, as previously found for small nucleolar RNAs (snoRNAs) 230 
produced by excision from a host gene transcript25: no additional guanines are found 231 
as the first nucleotide of CAGE tags mapping to the 5’ end of snoRNAs (Figure S12), 232 
as hypermethylation of the cap prevents base-pairing during reverse transcription.  233 
 234 
Excluding mirtrons, about half of the robust pre-miRNAs had a significant (P < 0.05) 235 
Drosha CAGE peak (52%, human, Figure 1a; 64%, mouse, Figure S1; see Methods 236 
for details). This percentage decreased from 56% for human pre-miRNAs satisfying 237 
all five of the miRBase high-confidence criteria to 37% if one of the criteria was 238 
violated, while only 7% of miRNAs in the permissive set had a Drosha CAGE peak 239 
(Figure 1a). Similar results were obtained for mouse (Figure S1). The analysis of 240 
Drosha CAGE peaks thus provided independent support for the stringency of the 241 
selection criteria used to define the FANTOM5 robust and permissive set of miRNAs. 242 
 243 
Discovery of candidate novel miRNAs 244 
To discover potential miRNAs that had not been described previously, the miRDeep2 245 
software26 was applied on all unannotated sRNAs (see Methods for details). In total, 246 
6,543 candidate miRNAs in human (Table S6, S7) and 1,444 in mouse (Table S8, S9) 247 
were identified. Most of the candidate miRNAs were lowly expressed, with fewer 248 
than 5% of them having sufficient tag counts on both arms of the pre-miRNA to 249 
enable a full evaluation of the high-confidence criteria (Table 2). The 282 human and 250 
34 mouse candidate miRNAs meeting at least 4 of the 5 high-confidence criteria 251 
formed the robust candidate set, while the permissive candidate set consisted of the 252 
remaining candidate miRNAs (Table S4 and Figure S13, human; Table S5 and Figure 253 
S14, mouse). The robust candidate set comprised 279 (human) and 33 (mouse) unique 254 
mature sequences, whereas the permissive candidate set provided an additional 5,826 255 
(human) and 1,354 (mouse) mature sequences. Nearly 11% of robust and 5% of 256 
permissive human candidate miRNAs had a significant (P < 0.05) Drosha CAGE 257 
peak (Figure S13; Figure S14 for mouse). Validation by qPCR of a selection of robust 258 
candidate miRNAs identified in monocyte and macrophage libraries confirmed their 259 
expression in these cell types in multiple donors (Figure S15, Table S10). 260 
 261 
The robust candidate set showed good concordance (127/282 or 45%) with the 3,524 262 
putative miRNAs identified recently in a study of tissue- and primate-specific 263 
miRNAs27, whereas the permissive candidate set yielded a smaller overlap (352/6,261 264 
or 6%). Few of these putative miRNAs27 had a significant Drosha CAGE peak 265 
(258/3,524 or 7%), which may be due to their low expression levels in the samples 266 
surveyed in FANTOM5. 267 
 268 
We conclude that the vast majority of canonical, highly expressed miRNAs had 269 
already been annotated. However, our analysis also provides evidence of extensive 270 
transcription of lowly expressed short RNAs from specific genomic loci. 271 
 272 
Expression variability of miRNAs in human primary cells 273 
The cell type dependence of expression of individual miRNAs was evaluated by 274 
analyzing the distribution of miRNA abundance across the FANTOM5 primary cells 275 
and tissues. First, we assessed various expression normalization strategies, and found 276 
that a counts per million (cpm) normalization (i.e., dividing the tag count of each 277 
miRNA by the total number of tags mapping to miRNA loci, and multiplying by 278 
1,000,000) yielded the best reproducibility between different donors for the same cell 279 
type, while maintaining the distinction in expression profile between different cell 280 
types (Figure S16; see Methods for details). We then created a miRNA expression 281 
table across the FANTOM5 samples for human (Table S11) and mouse (Table S12), 282 
using cpm normalization in our further analysis. Figure 2a shows a graphical 283 
overview of the human primary cells clustered by their robust miRNA expression 284 
profile using Miru28. An interactive heatmap of the expression data is available at 285 
http://fantom.gsc.riken.jp/5/suppl/De_Rie_et_al_2017/vis_viewer/#/heatmap.  286 
The expression levels of miRNAs varied greatly and were highly skewed, with on 287 
average five miRNAs contributing half of the total miRNA expression in a given 288 
library (Figure 2b, human; Figure S17, mouse), whereas most known and candidate 289 
miRNAs were lowly expressed (Figure 2c, human; Figure S18, mouse). The extreme 290 
distribution of miRNA expression across miRNAs and cell types was confirmed by 291 
qPCR (Figure S19). 292 
 293 
Cell ontology analysis 294 
A cell type specificity index, analogous to the previously defined tissue specificity 295 
index29, was calculated to quantify the cell type specificity of miRNA expression 296 
across the FANTOM5 collection of primary cell types (Table S13; see Methods for 297 
details). Previously described highly cell type specific miRNAs included miR-122-5p, 298 
miR-142-5p and miR-302a-5p, which were enriched in hepatocytes, leukocytes, and 299 
pluripotent stem cells, respectively (Figure 2d). In contrast, miRNAs such as miR-300 
100-5p and miR-29a-3p were broadly expressed but specifically depleted in particular 301 
cell types (leukocytes and pluripotent stem cells, respectively; Figure 2d). Candidate 302 
miRNAs tended to be restricted to specific cell types, with 80% of the robust 303 
candidate set and 96% of the permissive candidate set having a higher cell type 304 
specificity index than the median value for robust known miRNAs (Table S13). 305 
 306 
We then calculated the statistical significance of expression enrichment or depletion 307 
of each miRNA (Table S13) with respect to cell ontology clusters (Table S14) defined 308 
by the FANTOM5 cell ontology annotation30,31, which organizes FANTOM5 samples 309 
by cell type in a hierarchical framework (see Methods for details). Of miRNAs in the 310 
robust set, 54% had enriched expression in their most significant cell ontology cluster, 311 
whereas 27% were broadly expressed, with depleted expression in their most 312 
significant cell ontology cluster. The remaining 19% were lowly expressed without 313 
statistically significant enrichment or depletion in any cell ontology cluster; 314 
understanding their functionality may need profiling in further cell types or states. 315 
Pluripotent stem cells were characterized by cell type specific miRNAs, whereas cell 316 
type specific depletion of broadly expressed miRNAs was predominantly found in 317 
leukocytes. Examples of enriched expression not reported previously included miR-318 
488-5p in neural cells, miR-506-3p in light melanocytes, and miR-205-5p in epithelial 319 
cells. MiRNAs previously not reported as broadly expressed included miR-887-3p, 320 
which was present in most samples but was depleted in leukocytes. 321 
 322 
Identification of miRNA promoters 323 
We developed an automatic pipeline to identify miRNA promoters using Gencode 324 
v19 and RefSeq transcripts as candidate pri-miRNAs and the FANTOM5 CAGE data 325 
as putative transcription start sites (see Methods for details). This pipeline predicted 326 
promoters for 539 robust, 623 permissive, and 3,951 candidate pre-miRNAs in human 327 
(Table S15), and for 358 robust, 446 permissive, and 994 candidate pre-miRNAs in 328 
mouse (Table S16). Manual curation by two independent annotators confirmed the 329 
selected promoter for 512 (95%) robust pre-miRNAs; the computationally selected 330 
promoter was corrected for 26 pre-miRNAs and dropped for 1 pre-miRNA. Manual 331 
curation furthermore identified the promoter for an additional 196, mostly intergenic, 332 
pre-miRNAs, thereby generating the—to our knowledge—largest miRNA promoter 333 
collection to date (Table S17, Figure S20a). Across the human robust set, an 334 
associated ENCODE RAMPAGE (RNA Annotation and Mapping of Promoters for 335 
the Analysis of Gene Expression32) 5’ end was found within 300 base pairs of more 336 
than 75% of the FANTOM5 curated promoters both for intergenic and intronic 337 
miRNAs, outperforming the miRGen33, Chang et al.14, miRStart34, and TSmiR35 338 
collections of miRNA promoter annotations (Figure S20b). The median distance 339 
between the FANTOM5 annotated miRNA promoter and the associated RAMPAGE 340 
5’ end was 1 nucleotide, and was thereby closer than any of the existing miRNA 341 
promoter annotations (Figure S20c). RACE experiments confirmed that the transcripts 342 
generated at the identified promoter extended to the mature miRNA for 6 out of 7 343 
miRNAs (Figure S21, Table S18). RNA-seq data14 of cells expressing a dominant-344 
negative Drosha protein provided additional evidence for the FANTOM5 annotated 345 
pri-miRNAs, with 483 out of 607 pri-miRNAs (80%) having a 5’ end within 300 base 346 
pairs of an RNAseq transcript assembly extending to the mature miRNA locus (Figure 347 
S22). 348 
 349 
Both in human and in mouse, promoter sequences of intronic and intergenic miRNAs, 350 
like those of transcription factor genes, were highly conserved across species 351 
compared to the promoter sequences of protein-coding genes and of long non-coding 352 
RNAs (Figures 3a and S23, human; Figure S24, mouse). The distance between the 353 
transcription start site of the pri-miRNA and the mature miRNA locus was strongly 354 
conserved between human and mouse both for intergenic miRNAs and for intronic 355 
miRNAs (Figures 3b and S25). While this suggests that pri-miRNA transcripts may 356 
have some functional role beyond providing the substrate for pre-miRNA excision, 357 
there was no evidence of substantially elevated sequence conservation across species 358 
in pri-miRNAs (Figure S26). 359 
 360 
Correlation of mature miRNA and pri-miRNA expression levels 361 
The expression levels of mature miRNAs correlated with the CAGE expression levels 362 
of the associated promoter, with comparable correlation values for intergenic and 363 
intronic miRNAs (Figure 3c and S27; Table S19). The correlation was substantially 364 
higher for highly differentially expressed miRNAs, and exceeded correlations found 365 
for previously published14,33-35 miRNA promoter annotations (Figure S20d). About 366 
11% of pri-miRNAs in human were polycistronic, containing multiple mature 367 
miRNAs with highly correlated expression levels (Figure 3d and S28). Together this 368 
suggests that miRNA expression is primarily regulated at the transcriptional level.  369 
 370 
Using the CAGE expression level of the pri-miRNA as a proxy for the mature 371 
miRNA expression level, we extended the FANTOM5 miRNA expression atlas to the 372 
full breadth of the 1,829 (human) and 1,029 (mouse) libraries in the FANTOM5 373 
CAGE expression compendium17-19. This allowed us to assess miRNA expression 374 
also in samples for which only a CAGE library was available, covering an additional 375 
49 primary cell types, 245 cell lines, 138 tissue types, and 13 time courses in human, 376 
and an additional 48 primary cell types, 1 cell line, 234 tissue types, and 12 time 377 
courses in mouse. A cell ontology analysis was performed using the CAGE 378 
expression pattern of each human pri-miRNA (Tables S15 and S17) across 338 cell 379 
ontology clusters (Table S20) encompassing 636 CAGE libraries. This showed 380 
enriched expression of mir-202 in gonad, of mir-208a, known to be a key regulator of 381 
cardiac function37, in heart, as well as of multiple miRNAs in brain, including mir-382 
488, mir-556, and mir-885. Lastly, the CAGE data allowed us to measure the 383 
individual contribution of each paralog to the expression of miRNAs encoded 384 
multiple times in the human genome, providing evidence for differential regulation of 385 
paralogs in different cell types and tissues. For example, we found that mir-128-1 was 386 
expressed in most samples, while its paralog mir-128-2 was highly enriched in brain 387 
(Figure 3e). 388 
 389 
Transcriptional regulation of miRNA expression 390 
The accuracy of the predicted miRNA promoter regions was assessed using the Motif 391 
Activity Response Analyis (MARA) framework38 (outlined in Figure S29 and 392 
Methods). Using this framework, the expression levels of mature miRNAs were 393 
predicted based on the presence of putative transcription factor binding sites in the 394 
identified miRNA promoter region, and compared to the expression levels of the 395 
mature miRNAs observed in the sRNA libraries. The prediction accuracy of the 396 
FANTOM5 miRNA promoter atlas outperformed those of previously published 397 
miRNA promoter annotations14,33-35 (Figure S20e).  398 
 399 
Discussion 400 
MicroRNAs are key factors that contribute to cellular regulation by targeting specific 401 
transcripts for translational repression or for degradation. Advances in sequencing 402 
technology led to an increase in sequencing depth from nearly 1,300 reads per sRNA 403 
libraries in the first miRNA atlas39 to nearly 4.4 million reads per library in 404 
FANTOM5, allowing an accurate measurement of the expression even of lowly 405 
expressed miRNAs. These lowly expressed miRNAs may be abundant in a few cells 406 
in the population sampled, or in cell types, cell lines, or cellular conditions that are not 407 
included in our sample collection. Alternatively, they may be a signature of the 408 
ongoing evolution of the human miRNA repertoire. In particular, pervasive 409 
transcription of mammalian genomes22,40,41 generates a large number of hairpin 410 
secondary structures, which are prevalently encoded in the genome, that can act as 411 
substrates for processing by Drosha in the nucleus and Dicer in the cytoplasm. 412 
Whereas the majority of the sRNAs thus generated may be evolutionarily neutral and 413 
remain lowly expressed, some of them may provide a selective advantage, develop 414 
higher expression levels during evolution42, and become fixed in the genome as core 415 
miRNAs. Finally, we note that in spite of the breadth and depth of the FANTOM5 416 
sRNA sequencing data, most sRNAs currently annotated as miRNAs failed multiple 417 
high-confidence criteria, and may belong to a different class of short non-coding 418 
RNAs, such as transcription initiation RNAs23 or DNA damage response RNAs43, or 419 
may be degradation products44. 420 
 421 
Compared to existing miRNA expression atlases29,39, the FANTOM5 atlas covers the 422 
widest range of normal primary cells, enabling detailed analyses of miRNA 423 
expression and their contribution to establishing and maintaining cell type identity. 424 
The candidate miRNAs not reported previously were in particular highly cell type 425 
specific, and may therefore be missed in miRNA profiling studies in tissues rather 426 
than in specific cell types. 427 
 428 
We found extensive evidence that CAGE peaks observed at the Drosha cleavage site 429 
are due to the downstream RNA fragment generated by Drosha processing of the pri-430 
miRNA. Analysis of these CAGE tags suggested that these RNA fragments do not 431 
have a 7-methylguanosine cap, but may instead be uncapped or, alternatively, have a 432 
non-canonical cap. For polycistronic pri-miRNAs, such a cap may play a role in 433 
preventing rapid degradation of the downstream fragment, which itself may contain 434 
miRNAs. 435 
 436 
The MARA analysis allowed us to predict miRNA expression levels based on the 437 
regulatory motifs found in the miRNA promoter region, indicating that transcriptional 438 
regulation plays a central role in governing miRNA expression levels. Comparing the 439 
promoters of miRNAs, protein-coding genes, and long non-coding RNAs showed 440 
similar prevalences of transcription factor binding sites in proximal promoter regions 441 
(data not shown), suggesting that the basic mechanisms of transcriptional regulation 442 
are largely the same for these three classes of gene products. The identification of 443 
miRNA promoter regions as described in this work therefore paves the way for a 444 
detailed analysis of the transcriptional regulation of miRNA expression using the 445 
same computational and experimental methods that have previously proven their 446 
efficacy in the analysis of gene expression. 447 
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Figure 1: Selection of robust miRNAs and Drosha CAGE peak analysis. 594 
(a) Number of miRBase high-confidence rules (Table 2) satisfied by human pre-595 
miRNAs annotated in miRBase (n = 1,871). Pre-miRNAs with a statistically 596 
significant (P < 0.05) Drosha CAGE peak are shown in orange; mirtrons are shown in 597 
yellow. (b) Genomic locus of mir-223 in human with the total number of FANTOM5 598 
(blue) and ENCODE (red) CAGE tags as a function of the genomic position of their 599 
5’ end, showing a Drosha CAGE peak at the 3’ end of the pre-miRNA. FANTOM5 600 
sRNA reads are shown at the bottom, colored by their read count as defined by the 601 
color bar. The exact extent of the pre-miRNA was determined from FANTOM4 full-602 
length sequencing data23. (c) Number of CAGE tags as a function of their starting 603 
position relative to the 3’ end of the pre-miRNA, averaged across human pre-miRNAs 604 
in the robust set (n = 795). The 3’ end of the pre-miRNA was selected as the 3’ end of 605 
the most prevalent sRNA on the 3’ arm of the pre-miRNA in the FANTOM5 sRNA 606 
data, with the position indicated as zero corresponding to the first nucleotide 607 
downstream of the 3’ end of the pre-miRNA. 608 
 609 
Figure 2: Expression profile and cell ontology analysis of mature miRNAs. 610 
(a) Miru28 visualization of FANTOM5 primary cell samples based on their expression 611 
profile of robust mature miRNAs. (b) Number of most abundant miRNAs 612 
contributing at least 50% of the total miRNA expression in each human sRNA library 613 
in FANTOM5 (n = 420). (c) Reverse cumulative distribution of the maximum 614 
expression across the FANTOM5 samples of human miRNAs in the robust set (n = 615 
735), permissive set (n = 999), and robust candidate set (n = 279). (d) Examples of 616 
miRNAs enriched or depleted in specific primary cell samples. Expression of miR-617 
122-5p, miR-142-5p, and miR-302a-5p was enriched in hepatocytes, leukocytes, and 618 
  
pluripotent stem cells, respectively; miR-100-5p and miR-29a-3p were broadly 619 
expressed, but depleted in leukocytes and pluripotent stem cells, respectively. 620 
 621 
Figure 3: Analysis of the curated miRNA promoters of miRNAs in the robust set. 622 
(a) (left panel) Sequence conservation of the human genome, evaluated as the average 623 
phastCons36 score, in the promoter region of non-coding pri-miRNAs (containing 624 
intergenic mature miRNAs; n = 132), coding pri-miRNAs (containing intronic mature 625 
miRNAs; n = 415), transcription factor (TF)-coding transcripts (n = 1,651), other 626 
protein-coding transcripts (n = 15,350), and long non-coding RNAs (n = 1,461). The 627 
sequence conservation of randomly selected genome regions is shown in gray. The 628 
shaded area corresponds to one standard deviation in the estimated mean phastCons 629 
score. (right panel) The average sequence conservation at promoter regions of 630 
miRNAs was higher than at the promoter regions of non-TF protein-coding genes 631 
(Mann-Whitney P = 2 × 10−16, two-sided) and of long non-coding RNAs (Mann-632 
Whitney P = 1 × 10−35, two-sided). Error bars correspond to one standard deviation in 633 
the estimated mean phastCons score. (b) Distance between the transcription start site 634 
of the pri-miRNA and the 5’ end of the first pre-miRNA is highly correlated between 635 
human and mouse both for coding (Spearman r = 0.90; n = 78; Student t = 18.27; P = 636 
2 × 10−29 two-sided) and for non-coding (Spearman r = 0.86; n = 27; Student t = 8.33; 637 
P = 1 × 10−8 two-sided) pri-miRNAs, suggesting strong conservation of the genomic 638 
extent of pri-miRNAs. (c) Expression levels of pri-miRNAs, as measured by CAGE, 639 
and mature miRNAs, as measured by sRNA sequencing, were highly correlated both 640 
for coding  (average Spearman r = 0.25; n = 362; P = 2 × 10−53, Mann-Whitney U 641 
test, one-sided) and non-coding (average Spearman r = 0.27; n = 180; P = 1 × 10−30, 642 
Mann-Whitney U test, one-sided) pri-miRNAs, compared to a background 643 
  
distribution consisting of correlations between randomly paired pri-miRNAs and 644 
mature miRNAs. Correlations for polycistronic pri-miRNAs were averaged across the 645 
mature miRNAs. (d) Expression levels between mature miRNAs originating from the 646 
same pri-miRNA are highly correlated (average Spearman r = 0.74; n = 1,372; P < 647 
10−100, Mann-Whitney U test, one-sided), compared to a background distribution 648 
consisting of correlations between mature miRNAs originating from different pri-649 
miRNAs. (e) Cell type-dependent expression of miRNA paralogs: While mir-128-1 650 
was broadly expressed across most primary cell samples in FANTOM5, its paralog 651 
mir-128-2 was enriched in brain samples. (c-d) The box extends from the lower to the 652 
upper quartile, with the center line at the median; the whiskers indicate the full range 653 
of the data. 654 
 655 
  656 
  
Table 1. 657 
Human sRNA data sets analyzed in this study. 658 
Origin Data collection Number of samples Number of cell types 
Primary cells FANTOM5 293 118 119 Fort et al.19 6 3
ES cells Fort et al.19 6 1 
iPS cells Fort et al.19 6 1 
Tissues FANTOM5 6 4 tissues 
Time courses FANTOM5 87 6 time courses 
Total number of sequenced reads: 1,519,621,910 
  659 
  
Table 2. 660 
The miRBase high-confidence rules12. As a meaningful evaluation of the second, 661 
third, and fourth rule relies on accurate knowledge of the position and extent of the 662 
mature miRNA on both strands of the pre-miRNA, we evaluated these three rules 663 
only if the first rule was satisfied.  664 
1. 
≧ 10 tags on each arm of the pre-miRNA, or 
≧ 100 tags on one arm of the pre-miRNA, with ≧ 5 tags on the other arm 
2. ≧ 50% of the tags on each arm of the pre-miRNA have the same 5’ end 
3. 0–4 nt overhang at the mature 3’ end on each arm 
4. ≧ 60% of nucleotides of the mature sequence on each arm are base-paired  
5. ΔG < −0.2 kcal/mole/nucleotide 
 665 
  666 
  
Methods 667 
Samples and library preparation 668 
Short RNA libraries were prepared following the Illumina TruSeq Small RNA Sample 669 
Preparation protocol (catalog number RS-200-0012, RS-200-0024, RS-200-0036, RS-670 
200-0048) using the same RNA samples from which CAGE libraries were produced 671 
previously17,18, as well as one additional RNA sample without a matching CAGE 672 
library. RNA samples not previously described are listed in Table S2. TruSeq Small 673 
RNA Sample Prep Index Sequences were used as bar codes to allow pooling of 674 
multiple samples in one library. The short RNA libraries were sequenced using the 675 
Illumina HiSeq2000 sequencer in single-read, 50 base mode. The metadata of all 676 
FANTOM5 RNA samples, including those used for sRNA sequencing, are available 677 
in the FANTOM5 Semantic catalog of Samples, Transcription initiation And 678 
Regulators45  (SSTAR; http://fantom.gsc.riken.jp/5/sstar). SSTAR sample pages also 679 
provide links to the FANTOM5 miRNA expression atlas web interface.  680 
 681 
Data processing 682 
We extracted the short RNA sequences from the raw sequences using in-house scripts. 683 
We removed linker artifact sequences using TagDust46 version 1.13, ribosomal 684 
sequences using rRNAdust17 version 1.00, and filtered against mature tRNAs, 685 
ribosomal RNA, and 7SL RNA using global alignment. We mapped the remaining 686 
sequences using the Burrows-Wheeler Alignment (bwa) tool47 version 0.5.9-r16 to 687 
genome assembly hg19 (human) or mm9 (mouse), including chromosome Y if the 688 
donor was known to be male. Table S3 shows the number of short RNA sequences 689 
mapped to the genome for each sample. Two samples had fewer than 100,000 mapped 690 
tags and were discarded from the further analysis. 691 
  
 692 
Short RNA annotation and filtering 693 
We used release 21 of the miRBase database12, lifted over to genome assembly hg19 694 
(human) or mm9 (mouse), as our reference set of known miRNAs. Four pre-miRNAs 695 
in human that could not be lifted over to genome assembly hg19 and an additional six 696 
human pre-miRNAs that were lifted over to unplaced chromosomes were excluded 697 
from the analysis. We annotated all mapped short RNA reads mapping to genomic 698 
loci for ribosomal RNA, tRNAs, the RNA component 7SL of the signal recognition 699 
particle, small nuclear RNAs, small nucleolar RNAs, small Cajal body-specific RNA, 700 
small cytoplasmic RNAs, and piRNAs. We corrected for cross-mapping as described 701 
previously48, discarding all mappings to unannotated loci if the short RNA sequence 702 
could be mapped to an annotated locus instead. 703 
 704 
Drosha CAGE peak analysis 705 
We calculated the total number of CAGE tags starting at each genomic position across 706 
all 1,885 (human) and 1,202 (mouse) FANTOM5 CAGE libraries17,18, as available at 707 
http://fantom.gsc.riken.jp/5/datafiles/latest/basic/, as well as all 145 human ENCODE 708 
CAGE data22, which we downloaded from 709 
http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeRikenCage/. 710 
We defined the 3’ end of the pre-miRNA as the 3’ nucleotide of the mature miRNA 711 
on the 3’ arm of the pre-miRNA; the expected Drosha cleavage site is immediately 712 
downstream of this nucleotide. For each pre-miRNA in the robust set, we calculated, 713 
for each position with respect to the expected Drosha cleavage site, the total number 714 
of CAGE tags in the CAGE libraries. We normalized by dividing by the sum over the 715 
positions to obtain the CAGE profile with respect to the expected Drosha cleavage 716 
  
site for each pre-miRNA. We then summed the CAGE profiles across the pre-717 
miRNAs to obtain the average CAGE profile with respect to the expected Drosha 718 
cleavage site. Based on this profile, we selected a 9-basepair window between -2 and 719 
+7 base pairs with respect to the expected Drosha cleavage site for the FANTOM5 720 
CAGE data, and an 8-basepair window between -2 and +6 base pairs for the 721 
ENCODE CAGE data, as the Drosha CAGE peak window for a given pre-miRNA.  722 
For each pre-miRNA, we counted the number of CAGE tags with a 5’ end within this 723 
window, as well as the number of CAGE tags with a 5’ end anywhere between the 724 
pre-miRNA boundaries. Since CAGE tags tend to occur in clusters on the genome, we 725 
expect the distribution of the CAGE tag counts to be heavily overdispersed compared 726 
to the Poisson distribution. We therefore used the negative binomial distribution 727 
instead, with the dispersion parameter r estimated by fitting the distribution to the 728 
number of CAGE tags in any 8- or 9-basepair window on the human or mouse 729 
genome. This resulted in a dispersion of 1.856943 and 1.616542 for the FANTOM5 730 
human and mouse CAGE data, respectively (using a 9-basepair window), and 731 
0.325001 for the ENCODE CAGE data (using a 8-basepair window). Using these 732 
dispersion values, we calculated the statistical significance of the FANTOM5 and 733 
ENCODE CAGE peaks given the number k of CAGE tags within the window, the 734 
number K of CAGE tags within the pre-miRNA, the window size w, as well as the 735 
genomic extent L of the pre-miRNA as Ip(k, r), where I is the regularized incomplete 736 
beta function and p = μ / (r + μ), with μ = w K / L the expected number of tags at the 737 
Drosha CAGE peak under the null hypothesis. 738 
For human, we calculated an overall statistical significance value by combining the 739 
FANTOM5 and ENCODE statistical significance into a single P-value using Fisher’s 740 
method. 741 
  
The relative occurrence of CAGE tags in different subcellular fractionations (Figure 742 
S9) and the bias in the first nucleotide of CAGE tags (Figure S12) were evaluated for 743 
pre-miRNAs in the robust set with a statistically significant Drosha CAGE peak. 744 
 745 
Identification of candidate novel miRNA 746 
Candidate novel miRNAs were identified using miRDeep226, resulting in 7,461 747 
(human) and 2,034 (mouse) predicted pre-miRNAs, including 918 (human) and 590 748 
(mouse) known pre-miRNAs. To avoid predicted miRNAs from failing the miRBase 749 
high-confidence rules due to flaws in the predicted secondary structure, we repeated 750 
the secondary structure calculation for each predicted miRNA by applying RNAfold49 751 
version 2.1.2 on the sequence of the precursor miRNA while constraining the 752 
structure by allowing nucleotides in each arm of the hairpin to only base-pair to 753 
nucleotides in the other arm of the hairpin. In the comparison of the candidate novel 754 
miRNAs with the 3,524 tissue- and primate-specific miRNAs published recently27, we 755 
required the pre-miRNAs to overlap by at least 80%. 756 
 757 
Validation of candidate novel miRNA expression by qPCR 758 
Fresh buffy coat was obtained from the Red Cross following approval from the human 759 
research ethics committee of The University of Melbourne (ethics ID 1646608.1) and 760 
material supply agreement with Red Cross (16-05VIC-21). 761 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat using 762 
Ficoll hypaque (GE Healthcare, Uppsala, Sweden) as described previously50. CD14+ 763 
human monocytes were isolated from PBMC using human CD14+ magnetic beads 764 
(Milteny Biotec, Sydney, New South Wales, Australia). CD14+ monocytes were 765 
differentiated to macrophages in complete RPMI1640 media supplemented with 10% 766 
  
fetal calf serum and 100 ng ml−1 human macrophage colony-stimulating factor (M-767 
CSF) (PeproTech, Rehovot, Israel) for 5 days. Suspended cells were removed and 768 
adherent cells were washed with PBS before macrophages were collected. 769 
MicroRNAs were isolated from monocytes and macrophages using mirVana miRNA 770 
Isolation Kit (Life Technologies, Melbourne, Victoria, Australia) following the 771 
manufacturer’s protocol. Briefly, cells were lysed in lysis buffer followed by phenol 772 
extraction, and miRNAs were isolated from the phenol aqueous phase using a spin 773 
column followed by elution in RNase-free water. Following manufacturer’s protocol, 774 
cDNA synthesis was performed using miScript PCR Starter Kit (Qiagen, Hilden, 775 
Germany) by ligating a poly(A) tail to the miRNA followed by reverse transcription 776 
in the presence of universal tag. Samples without reverse transcriptase but with all 777 
other components were included and used as negative controls.  778 
Forward primers specific to the candidate novel miRNAs were designed using 779 
miRprimer51 (Table S10). Real-time PCR was performed using miScript PCR Starter 780 
Kit (Qiagen, Hilden, Germany) and following the manufacturer’s protocol.  The PCR 781 
reaction was set up with the custom-made forward primers and the universal reverse 782 
primer supplied with the kit. No-template controls and cDNA samples without reverse 783 
transcriptase were included as negative controls. Thermal cycling was performed as 784 
suggested by the manufacturer’s protocol.   785 
The expression levels of a wide range of miRNAs have been analyzed using our 786 
miRNA PCR assay in order to evaluate the sensitivity of the assay and determine the 787 
confidence of our results. Short RNAs commonly used as a reference, including 788 
RNU6 and let-7a-5p (ref. 52), showed relatively high expression levels. Other 789 
miRNAs that are highly conserved in metazoans or known to be expressed in myeloid 790 
cells, including miR-191-5p (ref. 53), miR-15a-5p (ref. 54), miR-206 (ref. 55), miR-791 
  
335-5p (ref. 56) and miR-339-3p (ref. 56), were included and used as positive 792 
controls, and showed moderate expression levels. Expression levels of miRNAs 793 
reported to be cell markers for other cell types and assumed to be lowly expressed in 794 
myeloid cells, including miR-153-3p (ref. 57) and miR-345-5p (ref. 58), were also 795 
analyzed in order to determine the detection limit of the assay. Our results 796 
demonstrate that the miRNA PCR assay could specifically detect the presence of the 797 
target miRNAs, and measure a wide spectrum of expression levels. The expression 798 
levels of the selected candidate novel miRNAs fell within the detection spectrum of 799 
our miRNA PCR assay, proving the reliability of our results.    800 
 801 
Evaluation of miRNA expression normalization strategies 802 
We counted the number of short RNA sequences with a length between 18 and 25 803 
nucleotides overlapping the mature miRNA loci in each of the primary cell samples. 804 
We then applied the following normalization strategies: 805 
• CPM (counts per million): Divide the count by the sum of counts for mature 806 
miRNAs in the robust set, and multiply by 1,000,000; 807 
• TMM (trimmed mean of M values): Apply the “calcNormFactors” function in 808 
edgeR59 with method “TMM” to the table of counts; 809 
• RLE (relative log expression): Apply the “calcNormFactors” function in 810 
edgeR59 with method “RLE” to the table of counts; 811 
• DESeq (effective library size): Apply the “estimateSizeFactorsForMatrix” 812 
function in DESeq60 to the table of counts; 813 
• UQ (upper quantile normalization): Divide the count by the sum of the counts 814 
of the top-25% most abundant miRNAs in each sample; 815 
  
• UD (upper decile normalization): Divide the count by the sum of the counts of 816 
the top-10% most abundant miRNAs in each sample. 817 
To evaluate each normalization strategy, we divided the primary cell samples in 818 
FANTOM5 into groups (n = 96) of independent donors of the same cell type. For 819 
each cell type group, we calculated the variance for each miRNA across the donors. 820 
To find the error between different cell types, we first calculated the average 821 
expression for each miRNA across donors in each cell type group, and then calculated 822 
the difference in the average expression between each pair of cell type groups (n = భమ × 823 
96 × 95 = 4,560) for each miRNA. To evaluate the total error, we calculated the mean 824 
squared error across miRNAs for each cell type group, as well as the mean squared 825 
error across miRNAs for each pair of cell type groups, and took the square root of 826 
each to find the root mean square (RMS) with cell type groups and between cell type 827 
groups (Figure S16a). We averaged the RMS error over the n = 96 cell type groups, 828 
and over the n = 4,560 pairs of cell type groups, and calculated the ratio of the 829 
average RMS error within cell types to the average RMS error between cell types 830 
(Figure S16b). To evaluate the standard error (Figure S16c), we calculated the mean 831 
square error across cell type groups for each miRNA, as well as the mean squared 832 
error across pairs of cell type groups for each miRNA, took the square root, and 833 
plotted the resulting RMS value for each miRNA against its mean expression level. 834 
We then used linear regression to calculate the slope of the RMS error within each 835 
cell type and between different cell types as a function of the miRNA expression 836 
level. Dividing these two slopes yielded the ratio in RMS error within cell types and 837 
between different cell types, normalized by miRNA expression level (Figure S16d). 838 
 839 
Clustering and visualisation of miRNA expression patterns 840 
  
MicroRNAs were clustered based on their expression patterns using the network 841 
visualisation and analysis tool Miru28 (http://kajeka.com/miru/miru-about/). The 842 
Pearson correlation was calculated for each pair of miRNAs. A modified 843 
Fruchterman-Rheingold algorithm was used to lay out the network graph in 3-844 
dimensional space, in which 502 nodes representing miRNAs were connected by 845 
3,369 weighted, undirected edges representing correlations of at least 0.6 between 846 
expression patterns. Areas of high connectively and correlation, representing groups 847 
of miRNAs with similar expression profiles, were identified using the Markov 848 
clustering algorithm (MCL) with an MCL inflation value of 2.2. Clusters were 849 
manually annotated based on the cell type or tissue of greatest expression.  All nodes 850 
in one cluster and the label describing the cluster are shown in the same color. The 851 
smallest labeled cluster contains six nodes; for clarity, smaller clusters have not been 852 
labeled but can be identified by groups of nodes of the same color. 853 
 854 
Validation of miRNA expression quantitation by qPCR 855 
Expression of selected miRNAs was measured using the TaqMan® MicroRNA Assay 856 
(Applied Biosystems) according to its protocol. RNA samples 11544, 11624, 11705 857 
(CD19+ B cells, donor1, 2, and 3), 11269, 11346, 11418 (dermal fibroblast donor1, 2, 858 
and 3), 12626 (H9 embryonic stem cells), and 11523, 11603, 11684 (hepatocyte 859 
donor1, 2, and 3) (Table S3) were used after confirmation of the RNA quality by 860 
measuring the RIN value using a TapeStation and the 260/280 and 260/230 ratios 861 
using NanoDrop. The Ct values obtained were normalized against the Ct value of 862 
small nucleolar RNA SNORD48. 863 
 864 
Cell type specificity index 865 
  
Following the definition of the tissue specificity index (TSI) 29, we define the cell type 866 
specificity index of miRNA j as 867 
index j =
1
N −1
1−
xj,i
max
i '
x j, ′i






i=1
N  868 
where N is the number of primary cell types in FANTOM5, and xj,i is the expression 869 
in counts-per-million of miRNA j in cell type i, averaged over independent donors. 870 
 871 
Guide strand selection 872 
For each pre-miRNA, we designated the hairpin arm with the highest expression level 873 
(in counts-per-million) in any of the FANTOM5 samples as the guide strand, and 874 
refer to the opposite arm as the passenger strand. 875 
 876 
Cell ontology analysis 877 
We used the FANTOM5 cell ontology30,31 to create cell ontology clusters (Tables S14 878 
and S20). We performed a likelihood-ratio test comparing the expression data 879 
between the samples in each cell ontology cluster and the background, consisting of 880 
all other samples listed in Tables S14 and S20, modeling the tag counts by a negative 881 
binomial distribution. For each miRNA, we selected the three cell ontology terms for 882 
which the expression in the cell ontology cluster compared to the background was 883 
statistically most significantly higher, and the three cell ontology terms for which the 884 
expression in the cell ontology cluster compared to the background was statistically 885 
most significantly lower. The P-values listed in Tables S13, S15, and S17 for each 886 
miRNA for specific cell ontology clusters were not corrected for multiple testing. 887 
 888 
Identification of miRNA promoters 889 
  
Candidate pri-miRNAs consisted of transcripts annotated in Gencode61 v19 (human) 890 
or vM5 (mouse) or in the NCBI Entrez Gene database62. For each pre-miRNA, we 891 
selected all candidate pri- miRNAs with a transcription start site upstream of the pre-892 
miRNA and a 3’ end downstream of the 5’ end of the pre-miRNA, and defined all 893 
FANTOM5 permissive CAGE peaks17 within the genomic region from 500 bp 894 
upstream of the 5’ end of the pri-miRNA to the 5’ end of the pre-miRNA as the set of 895 
candidate promoters associated with the pre-miRNA. We averaged the expression 896 
level (in tags-per-million) of each candidate promoter across all FANTOM5 CAGE 897 
samples, and selected the candidate promoter with the highest average expression 898 
level as the (computationally predicted) promoter of the miRNA. Each human 899 
miRNA in the robust set was manually curated by two annotators. 900 
 901 
Validation of miRNA promoters by RAMPAGE 902 
We downloaded all 212 BAM files containing ENCODE RAMPAGE sequencing data 903 
mapped to human genome assembly hg19 that were not marked as “low read depth” 904 
or “low replicate concordance”. We retained the 5’ end positions of RAMPAGE 905 
transcripts with a 3’ end within 1,000 basepairs of a pre-miRNA locus, discarding 5’ 906 
end positions supported by fewer than 5 RAMPAGE transcripts, and associated the 907 
remaining 5’ end positions with the pre-miRNA as putative transcription start sites. 908 
 909 
Validation of miRNA promoters by RACE 910 
We mixed 4.0 μl 5X First-Strand Buffer, 0.5 μl DTT (100 mM; Invitrogen, catalog 911 
number 70726), 1.0 μl dNTP Mix (20 mM), spun briefly in a microcentrifuge, and 912 
kept at room temperature. We combined 1.0-10.0 μl with 1 μg total RNA from 913 
monocytes, macrophages, and dendritic cells, 1.0 μl Random Primer Mix (N-15) (20 914 
  
μM), and 0-9 μl sterile water to reach a total volume of 11.0 μl in separate 915 
microcentrifuge tubes, mixed the contents and spun the tubes briefly. We incubated 916 
these tubes at 72 °C for 3 minutes, and then cooled to 42 °C for 2 minutes. After 917 
cooling, we spun the tubes for 10 seconds at 14,000 g to collect the contents at the 918 
bottom. Next, we added 1.0 μl of Smarter oligo (20 μM) per reaction, and mixed well 919 
by vortexing and spun the tube briefly in a microcentrifuge. We then added 0.5 μl 920 
RNase Inhibitor (40 U/μl; Invitrogen RNaseOUT™, catalog number 10777019) and 921 
2.0 μl SMARTScribe Reverse Transcriptase (100 U; Clontech, catalog number 922 
639537) to the buffer mix, and mixed these reagents at room temperature. Next, we 923 
added 8.0 μl of the master mix to the RNA solution, mixed the contents of the tubes 924 
by gently pipetting, and spun the tubes briefly. We incubated the tubes at 42 °C for 90 925 
minutes and heated the tubes at 70 °C for 10 minutes in a hot-lid thermal cycler. We 926 
then added 90 μl Tricine-EDTA buffer to each tube. 927 
We prepared the master mix for the first PCR by combining 2.5 μl of the cDNA 928 
solution, 5.0 μl 10X Advantage 2 PCR buffer (Clontech, catalog number 639207), 1.0 929 
μl dNTP Mix (10mM each) 50X Advantage 2 Polymerase Mix (Clontech), 1.0 μl of 930 
the smarterRACE_forward primer at 10 pmol/μl, 1.0 μl of the miRNA-specific outer 931 
primer (Table S18) at 10 pmol/μl, and added PCR-grade water to reach a volume of 932 
50 μl. We ran a 2-step PCR program consisting of 1 minute at 95 °C, 25 cycles of 30 933 
seconds at 95 °C followed by 70 seconds at 68 °C, 7 minutes at 68 °C, and finishing 934 
at 8 °C. We diluted 5 μl of the primary PCR product into 245 μl of Tricine-EDTA 935 
buffer. 936 
We prepared the master mix for the second PCR by combining 5.0 μl of the product 937 
of the first PCR after dilution with 5 μl of the 10X Advantage 2 PCR buffer, 1.0 μl 938 
dNTP Mix (10 mM), 1.0 μl of 50X Advantage 2 Polymerase Mix (Clontech), 2.0 μl of 939 
  
the Nextera_i7 primer, 2.0 μl of the miRNA-specific inner primer (Table S18), and 34 940 
μl of PCR-grade water. We ran a 2-step PCR program consisting of 1 minute at 95 °C, 941 
20 cycles of 30 seconds at 95 °C followed by 70 seconds at 68 °C, 7 minutes at 68 °C, 942 
and finishing at 8 °C. We diluted 5 μl of the PCR product into 245 μl of Tricine-943 
EDTA buffer. 944 
We prepared the master mix for the third PCR by combining 5.0 μl of the PCR 945 
product of the second PCR with 5.0 μl of 10X Advantage 2 PCR buffer, 1.0 μl dNTP 946 
mix (10 mM), 1.0 μl of 40X Advantage 2 Polymerase Mix (Clontech), 2.0 μl of the 947 
Nextera_i7 primer, 2.0 μl of the Nextera_i5 primer, and 34 μl of PCR-grade water. 948 
We purified by AMPure at a 1.8 ratio, checked 2 μl of the second PCR product on a 949 
TapeStation, kept the libraries at -20 °C until sequencing, and pooled the PCR 950 
products, each with a different barcode combination before paired-end sequencing on 951 
a MiSeq sequencer (Illumina). 952 
We mapped the sequencing data to the human genome using Blat63, merged each pair 953 
into a single mapped transcript, and retained transcripts that overlap an inner primer. 954 
The histograms in Figure S21 show the position of the 5’ end of these transcripts. 955 
 956 
Promoter sequence conservation analysis 957 
We previously compiled a list of transcription factors in human and mouse17. Protein-958 
coding genes and lncRNAs consisted of all other genes annotated in the NCBI Entrez 959 
Gene database62 as protein coding or miscRNA, respectively. For each gene in these 960 
three categories, we selected the associated p1 CAGE peak as defined previously17 as 961 
the gene promoter, and discarded all genes without an associated CAGE peak. We 962 
then found the phastCons conservation score36, obtained from the UCSC Genome 963 
Browser database64, for the alignment of 99 vertebrate organisms against the human 964 
  
genome hg19, as a function of position relative to the transcription start site for each 965 
gene and miRNA, and averaged these scores for each category at each position. 966 
 967 
Construction of the FANTOM5 miRNA expression atlas of miRNAs 968 
CAGE tag start site (CTSS) files31, excluding universal and whole body RNA 969 
samples, were downloaded from http://fantom.gsc.riken.jp/5/datafiles/latest/basic/. 970 
CAGE tag counts for technical replicates of the same RNA sample were summed for 971 
each genomic position. CAGE libraries published by Fort et al.19 were downloaded 972 
from DDBJ, accession DRA000914. The number of CAGE tags at each genome 973 
position were counted to generate CTSS files, and pri-miRNA expression tables were 974 
generated by summing the CAGE tags under each promoter, calculating the total 975 
number of tags mapped to the genome, and using this number to normalize to tags per 976 
million (tpm). 977 
Mature miRNA expression tables were generated by counting the number of sRNA 978 
tags to each miRNA locus, calculating the total number of tags mapping to the robust 979 
miRNAs, and using this number to normalize to counts per million (cpm). 980 
The CAGE and sRNA expression tables are available for download at the miRNA 981 
expression viewer at 982 
http://fantom.gsc.riken.jp/5/suppl/De_Rie_et_al_2017/ 983 
To generate the heatmap, we averaged the cpm-normalized expression values of each 984 
miRNA across donors for each cell type, and converted the expression profile of each 985 
miRNA to Z-scores by subtracting the mean and dividing by the standard deviation 986 
across cell types. The heatmap was sorted both for cell types and for miRNAs by 987 
performed centroid-linkage hierarchical clustering, using the Pearson correlation as 988 
the similarity measure. 989 
  
 990 
Motif activity response analysis (MARA) 991 
The genome-wide predictions of transcription factor binding sites were produced as 992 
described previously18. Briefly, we downloaded the whole-genome alignment of the 993 
human genome hg19 against 99 other vertebrate genomes, and of the mouse genome 994 
mm9 against 29 other vertebrate genomes, from the UCSC Genome Browser 995 
database64, and extracted the multiple alignments of human, macaque, mouse, rat, 996 
cow, horse, dog, opossum, and chicken. We divided the genome into segments and 997 
realigned each segment using T-Coffee65, and generated genome-wide transcription 998 
factor binding site (TFBS) predictions using MotEvo66 for the SwissRegulon set of 999 
position-weight matrix motifs67 (Figure S29a). We then counted the number of 1000 
predicted TFBSs for each motif in the –300 to +100 base pair base proximal promoter 1001 
regions of genes in the NCBI Entrez Gene database62, excluding all miRNA 1002 
promoters (Figure S29b). Next, we used MARA38 to decompose the FANTOM5 1003 
CAGE expression profiles of these promoters in terms of their associated motifs, 1004 
yielding the activity profile of each motif across the FANTOM primary samples 1005 
(Figure S29c). We then counted the number of TFBSs for each motif in the –300 to + 1006 
100 base pair base proximal promoter region of each miRNA (Figure S29d), and 1007 
predicted the miRNA expression level by calculating the weighted sum of the 1008 
activities for motifs found (Figure S29e). We compared the predicted expression 1009 
levels to the expression levels of the mature miRNA observed in the FANTOM5 1010 
sRNA sequencing data (Figure S29f) and calculated their correlation (Figure S29g) as 1011 
a measure of the accuracy of the miRNA promoter identification. Following the 1012 
MARA procedure38, we normalized the cpm expression values of miRNAs by adding 1013 
0.5, taking the base-2 logarithm, subtracting the mean across samples, and finally 1014 
  
subtracting the mean across miRNAs. We defined strongly differentially expressed 1015 
miRNAs, included in Figure S20d and S20e, as those that had a standard deviation in 1016 
expression, after normalization, across samples larger than 2. 1017 
 1018 
Data availability 1019 
Raw sequencing data of the sRNA libraries are available at the DNA Data Bank of 1020 
Japan (DDBJ; http://www.ddbj.nig.ac.jp/) under accession numbers DRA001101, 1021 
DRA002711, DRA003804, and DRA003807, and for the RACE experiments at the 1022 
NCBI Gene Expression Omnibus (NCBI GEO; https://www.ncbi.nlm.nih.gov/geo/) 1023 
under accession number GSE98695. 1024 
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